Mirador Therapeutics
Chris Schaumburg, PhD, MBA has an extensive background in the biosciences industry, with experience in various leadership roles focusing on business development, pipeline strategy, and research investigation. With a solid educational foundation, including a Ph.D. in Philosophy and an MBA, Chris has worked in companies like Mirador Therapeutics, Prometheus Biosciences, Urovant Sciences, Purple Life Laboratories, LLC, and Allergan. With a history of co-founding companies and leading teams, Chris brings a wealth of experience and expertise to the industry.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.